Home / Market News / $TEVA
fiscal.ai Corporate Catalyst Impact 75/100 ● positive

Teva and Samsung Bioepis Announce Agreement to Commercialize Two FDA-Approved Biosimilars in the U.S.

Nov 3, 2026, 1:02 PM UTC · Primary ticker $TEVA

Teva Pharmaceutical Industries has secured U.S. commercialization rights for two immunology biosimilars from Samsung Bioepis. This deal expands Teva's biosimilar portfolio and market reach, while Samsung Bioepis retains manufacturing and regulatory responsibilities, sharing in future profits.

Teva Pharmaceutical Industries has entered into a strategic agreement with Samsung Bioepis to commercialize two FDA-approved immunology biosimilars, infliximab-abda and ETICOVO (etanercept-ykro), in the U.S. This is significant as it immediately bolsters Teva's biosimilar pipeline and market presence in the lucrative immunology space, offering new revenue streams through profit-sharing. For Samsung Bioepis, it secures a strong commercialization partner for its manufactured products in a key market. Competitors like Johnson & Johnson (Remicade) and Amgen (Enbrel) face increased biosimilar competition, potentially impacting their market share and pricing power. In the short term, Teva will incur upfront payments, but the long-term outlook suggests potential for significant revenue growth and market penetration in the biosimilar segment, which is generally characterized by lower costs and increased patient access. A key opportunity for traders lies in Teva's potential to capture a larger share of the immunology market, while the risk for incumbents is erosion of their branded drug sales.

$TEVA positive Expands biosimilar portfolio and market share
$207940.KS positive Secures US commercialization partner for biosimilars
$JNJ negative Increased competition for Remicade (infliximab)
$AMGN negative Increased competition for Enbrel (etanercept)
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.